SCHEMBL3011422

SCHEMBL3011422

COc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4cc(F)ccc4C)CC3)n2)cc1OC

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.39
MAPT P10636 4/20 0.38
TP53 P04637 3/20 0.38
SMN1; SMN2 Q16637 5/20 0.36
L3MBTL1 Q9Y468 3/20 0.36
LMNA P02545 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
HCRTR1 O43613 1/20 0.35
HCRTR2 O43614 1/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
F2RL3 Q96RI0 1/20 0.34
KDM4E B2RXH2 2/20 0.34
TSHR P16473 1/20 0.34
KMT2A Q03164 2/20 0.34
POLB P06746 1/20 0.34
MCHR1 Q99705 1/20 0.34
ENPP1 P22413 1/20 0.34
ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3013021 0.92 AR (0.39) ARMAPTTP53SMN1; SMN2LMNA
SCHEMBL3012880 0.91 GPR6 (0.40) ARMAPTTP53SMN1; SMN2L3MBTL1
SCHEMBL3014084 0.90 RAB9A (0.38) ARMAPTTP53SMN1; SMN2LMNA
SCHEMBL3018837 0.90 NAAA (0.35) ARMAPTSMN1; SMN2L3MBTL1LMNA
SCHEMBL3008114 0.89 CTSS (0.42) ARMAPTTP53SMN1; SMN2L3MBTL1
SCHEMBL3016341 0.88 MAPT (0.38) ARMAPTTP53SMN1; SMN2LMNA
SCHEMBL3012971 0.88 SMN1; SMN2 (0.41) ARMAPTTP53SMN1; SMN2L3MBTL1
SCHEMBL3009006 0.88 SMN1; SMN2 (0.37) ARSMN1; SMN2L3MBTL1NPC1RAB9A
SCHEMBL3011191 0.88 NAAA (0.36) ARMAPTSMN1; SMN2L3MBTL1LMNA
SCHEMBL3007854 0.88 MAPT (0.43) ARMAPTTP53SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885MAPT 18/4885TP53 2880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.